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Abstract: The aggressive outbreak of the severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) as COVID-19 (coronavirus disease-2019) pandemic demands rapid and simplified
testing tools for its effective management. Increased mass testing and surveillance are crucial
for controlling the disease spread, obtaining better pandemic statistics, and developing realistic
epidemiological models. Despite the advantages of nucleic acid- and antigen-based tests such as
accuracy, specificity, and non-invasive approaches of sample collection, they can only detect active
infections. Antibodies (immunoglobulins) are produced by the host immune system within a few
days after infection and persist in the blood for at least several weeks after infection resolution.
Antibody-based tests have provided a substitute and effective method of ultra-rapid detection for
multiple contagious disease outbreaks in the past, including viral diseases such as SARS (severe
acute respiratory syndrome) and MERS (Middle East respiratory syndrome). Thus, although not
highly suitable for early diagnosis, antibody-based methods can be utilized to detect past infections
hidden in the population, including asymptomatic ones. In an active community spread scenario
of a disease that can provide a bigger window for mass detections and a practical approach for
continuous surveillance. These factors encouraged researchers to investigate means of improving
antibody-based rapid tests and employ them as reliable, reproducible, sensitive, specific, and economic
tools for COVID-19 mass testing and surveillance. The development and integration of such
immunoglobulin-based tests can transform the pandemic diagnosis by moving the same out of the
clinics and laboratories into community testing sites and homes. This review discusses the principle,
technology, and strategies being used in antibody-based testing at present. It also underlines the
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immense prospect of immunoglobulin-based testing and the efficacy of repeated planned deployment
in pandemic management and post-pandemic sustainable screenings globally.
Keywords: antibody; immunoglobulin; COVID-19; SARS-CoV-2; Point of Care Test; PoCT;
population surveillance
1. Introduction
The outbreak of coronavirus disease-2019 (COVID-19) has rapidly spanned the world, with over
39 million reported cases and 1 million deaths (as of 16 October 2020) across multiple countries [1].
The severity of the disease in diagnosed patients has broad variations ranging from asymptomatic
carriers, or mild cases needing supportive care, to severe cases requiring extracorporeal membrane
oxygenation [2]. The patients with symptom onset are reported to be most contagious and to shed the
virus [3]. However, as clinical testing capacities increase, numbers of asymptomatic or pre-symptomatic
cases keep skyrocketing. This jeopardizes proper screening and transmission-control. This especially
poses a serious challenge since governments and regulatory bodies relax stay-at-home orders and
reopen partially. In some cases, decision-makers are being forced to revert their reopening plans
on account of increasing case numbers. Surveillance and largescale accessible diagnostics always
play an important part to curb the spread of infectious pathogens and reduce mortality during an
outbreak such as this [4,5]. During past outbreaks, the lack of a rapid and simple serological test
limited past infection tracing and assessment of overall health impacts. A reliable immunoglobulin
(antibody)-based surveillance plan that can detect even past and non-active infections can help
understand community spread dynamics and the level of susceptibility in a specific population or
region [6]. These tests detect the presence of specific proteins called antibodies or immunoglobulins
produced in response to antigen/s of the pathogen [7]. Moreover, antibody-based diagnostic tests
at mass scale can help gather epidemiological data on infected cases, and track them for possible
COVID-19 associated complications such as cardiovascular [8–11], neurological [12–15], and other
unknown pathophysiological conditions [16].
To date, there are several strategies for diagnosing COVID-19, which are mainly based on
viral nucleic acid [17–20] or antigen detection [21], and detection of the host’s immunological
responses [22]. Figure 1 illustrates the most widely used diagnostic tests for COVID-19. All these
tests have their own advantages and shortcomings. Real-time polymerase chain reaction (RT-PCR),
despite its unbeatable accuracy and precision, has limitations such as the requirement of highly
trained technicians, laboratory equipment, and/or high expense and time required per test [23].
The shortage or unavailability of reagents for RNA extraction from the virus is another challenge [23].
Unlike RT-PCR, emerging reverse transcription loop-mediated isothermal amplification (RT-LAMP) can
complete the reactions within an hour, with limited resources, and without highly skilled technicians.
However, the efficacy of RT-LAMP, just like other molecular diagnostic methods such as recombinase
polymerase amplification (RPA) and clustered regularly interspaced short palindromic repeats-based
(CRISPR-based) detection, is largely limited by the precision in primer designs and specificity of other
tools [24]. Enzyme-linked immunoassay (ELISA)-based antigen or antibody detection is also limited
by lengthy protocols and the requirement of expensive lab equipment. Antigen tests are recently being
introduced as a rapid diagnostic tool to screen community spread of the pandemic [25]. Limit of
Detection (LoD) for antigen tests tend to be higher than that of nucleic acid amplification (NAA) [26].
Despite the questions regarding the sensitivity, among the currently available methods, lateral flow
antigen tests are the fastest and can be performed by any healthcare professional without additional
training [27].
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value of specificity and sensitivity, when performed repeatedly in conjunction with contact tracing, 
can prove valuable in formatting public policies and mass preventative measures during reopening 
phases [32,33]. Additionally, moving initial diagnosis for COVID-19 from a limited number to a large 
population can help understand community spread dynamics and disease history. That can, 
subsequently, facilitate obtaining the real statistics of the pandemic, providing better treatments and 
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Figure 1. Scheme showing the comparison of different methods used for COVID-19 diagnosis (PoCT: 
Point of Care Test). Nucleic acid tests detect the genetic material from the virus. To collect the infected 
cells, a nasal or throat swab of the patient is required. Through a series of chemical reactions, copies 
of viral genetic material are produced. It helps to analyze whether or not a person has active infection. 
Polymerase chain reaction (RT-PCR) and Reverse Transcription Loop-Mediated Isothermal 
Amplification (RT-LAMP) are two major tests used in nucleic acid analysis. In total, 3–4 hours are 
required to carry out RT-PCR. RT-LAMP is a simple method which can detect few copies of target 
nuclei sequences under isothermal conditions with the help of specially designed additional primer 
sets. It can be performed in laboratories or tested in point of care settings. RT-LAMP reaction can be 
Figure 1. Scheme showing the c aris f iffere t ethods used for COVID-19 diagnosis (PoCT:
Point of Care t). Nucleic acid tests detect th genetic material from the virus. To coll t the
inf cted cells, a nasal or throat swab of the patient is required. Through a series of chemical reactions,
copies of viral gene ic m t rial are produced. It helps to analyze whe her or not a person has active
infection. Polymerase chain reaction (RT-PCR) and Reverse Transcription Loop-Mediated Isothermal
Amplification (RT-LAMP) are two major tests u ed in nuclei acid analysis. In total, 3–4 h are required to
ca ry out RT-PCR. RT-LAM is a simple method which can detect few opies of arget nuclei sequences
under sothermal condit ons with the help of specially designed additional primer sets. It can be
performed in laboratories or tested in p int of care settings. RT-LAMP reaction can be completed
within an hour. A rapid antigen test is a rapid diagnostic test which detects the presence of viral
antigen usually in the nasopharyngeal samples. This is the newest method among the above described
tests. In this type of test, chemicals fragment the virus and then antibodies attached to a plate detect
these fragments. This provides relatively fast test results within 15 min. This again, helps to analyze
whether or not a person has active infection. Lateral flow and enzyme-linked immunosorbent assays
(ELISA) are the major types of antigen tests. Antibody tests help to detect past infections or those at
advanced stages. Lateral flow test is the commonly accepted cost-effective antibody test which does not
require any specialized equipment. It is a relatively fast method of testing, completed within 15–20 min.
This type of assay is performed on blood samples. ELISA is a laboratory-based antibody test which
requires skilled professionals and is a time-consuming task of 1–3 h. By this method, up to 96 samples
can be tested per batch.
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Both NAA and antigen-based tests can only diagnose currently active cases with significant
viral shedding. Antibody-based tests, on the other hand, can trace past infections. They are cheap,
uncomplicated, faster than RT-PCR (the universally accepted gold-standard for coronavirus diagnosis),
and can be deployed in remote areas. The testing tools can be easily acquired and standardized [28,29].
There are also published studies validating serological tests, including virus-specific IgM
(Immunoglobulin M) and IgG (Immunoglobulin G), during past viral epidemics such as SARS
(severe acute respiratory syndrome) [30,31]. An antibody-based test with a reliable threshold value of
specificity and sensitivity, when performed repeatedly in conjunction with contact tracing, can prove
valuable in formatting public policies and mass preventative measures during reopening phases [32,33].
Additionally, moving initial diagnosis for COVID-19 from a limited number to a large population
can help understand community spread dynamics and disease history. That can, subsequently,
facilitate obtaining the real statistics of the pandemic, providing better treatments and minimizing
the long-term manifestations of infection. Altogether, these can be potentially transformative in
formulating better predictive models and preventative policies to improve the quality of life during
post COVID-19 stage.
Several companies and research groups are validating, producing, and marketing lateral flow
antibody assays as rapid point-of-care tests to identify active COVID-19 cases [34]. However, the ability
of antibody tests to accurately detect exposure to the severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) relies on their sensitivity and specificity, which can vary significantly between different
assays. Furthermore, these tests are less likely to detect patients in the early stages of the disease.
Despite these factors, the widespread use of serology tests as rapid point of care tests (PoCTs) could reveal
the actual number of infections and infection mortality rates. These results can inform researchers of the
complete disease statistics and help in designing better epidemiological models. This article presents a
comprehensive review of the background and present developments in antibody-based mass testing.
It also emphasizes the profound importance of developing robust and accurate tests and how judicious
usage can serve the purpose of effective population surveillance and post-pandemic management.
2. The Relevance of Rapid Tests in a Pandemic Diagnosis and Surveillance
Diagnosis, as well as monitoring of diseases, are the essential factors for clinical management,
especially during outbreaks. The primary necessity in a pandemic scenario understandably constitutes
of easy, rapid, and field-deployable mass testing tools. The various attributes of quick testing approaches
that make them relevant are:
(i) They can be accessed in rural and urban settings, developed, and developing countries alike,
like a simple blood glucometer or pregnancy strip test.
(ii) They can be used for the mass diagnosis utilizing rapid tests that prevent patient leakage as
diagnosis and following remediation steps can happen simultaneously.
(iii) They can significantly reduce the turnaround time for test results, which becomes crucial in a
community transmissible disease outbreak.
(iv) They can be combined with biostatistical and bioinformatics analysis, which facilitate the quick
recording of an enormous number of test results, data storage for easy reference and practical use
for constant patient monitoring.
In past episodes of viral and non-viral contagious disease outbreaks, conventional methods
such as biochemical assays, pathogen culturing, ELISA, RT-PCR, and other nucleic acid amplification
tests (NAATs) [35] have played a significant role. Their major negative aspects are that they are
time-consuming and expensive [36]. Moreover, such tests were not suitable to identify or track
past infections for recognizing and mitigating the after-effects of the infection on a community
basis. Nonetheless, during an ever-evolving transmissible viral pandemic, such as the current one,
complete community-based initial diagnosis is not practicable, especially for asymptomatic patients.
In view of that fact, antibody-based rapid tests can be the first line of practicable mass testing.
J. Clin. Med. 2020, 9, 3372 5 of 26
Compared to laboratory-based thorough testing protocols, which can be used for a greater accuracy
on a shortlisted number of patients, a rapid test poses a considerable advantage. Rapid tests such as
antibody-based ones also have a great prospect in mass surveillance or in past infection screening from
a public health perspective [37].
3. Evolution of Antibody-Based Mass Testing
In 1917, Dochez and Avery were the first to report the utilization of immunoassay at a mass scale
for the diagnosis of infectious diseases while testing for pneumococcal polysaccharide in patients with
lobar pneumonia [38]. The introduction of radioimmunoassay (RIA) in 1960 and the ELISA in 1971
added higher sensitivity to the immunoassays for antigen or antibody-based disease diagnosis [39–41].
Subsequent early innovations comprised of immunoassays dependent on capillary migration in
cellulose acetate sheets as a structural support, and coupling of antibodies to colloidal gold or
latex [42,43]. Further, progress in this field resulted in the development of more advanced technologies
such as the lateral flow immunoassay (LFIA) platform [44–46] (Figure 2). Sandwich immunoassays
have been the basis for the development of rapid diagnostic tools for various infectious diseases [47–50].
The test kits for HIV-1/2 or hepatitis C virus follows a LFIA format that consists of a strip of an
immobilized target antigen to which the patient antibodies bind [51–55]. A labeled reporter, such as a
second targeted antibody is used for detecting the patient antibody.
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Figure 2. Scheme showing the general ste i tibody-base diagnosis of viral infections from
blood samples. Rapid antibody tests are perf r e si g bl od samples. After the addition of diluent
buffer, the sample/diluent mixture flows do n to the sa ple pad by capillary action/lateral flow and
hits the conjugation pad. The conjugation pad contains the viral antigen conjugated to a specific label
molecule or nanoparticles. During this stage, any antibodies in the sample with specificity for the virus
will bind to the antigen and its conjugated label. Next, the sample/conjugate complex moves to the
nitrocellulose membrane. Here, it meets the three test lines: IgG, IgM, and control. First is the M line,
which contains an immobilized antibody that recognizes human IgM. Any IgM antibodies will bind
here. However, only human IgM antibodies specific for the viral infection form antigen/label complexes
which will produce a visible colored line. Second is the G Line, which contains an immobilized antibody
that recognizes Human IgG. All IgG antibodies will bind here. However, only human IgG antibody/virus
specific antigen/label complexes will produce a visible colored line. The control line is the last line the
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sample will encounter. The control line contains an immobilized antibody that recognizes Rabbit IgG,
the control antibody. To serve as a procedural control, a colored line should always appear in the
control line region, indicating that the proper volume of specimen has been added and membrane
wicking has occurred. Generally, the results can be read after 10 min.
Several tests obtained a Clinical Laboratory Improvement Amendments (CLIA) waiver that
permitted their largescale use as rapid test tools and could be adopted even by the least developed
nations [52,56]. The OraQuick Advance Rapid HIV-1/2 antibody test is an FDA approved test for
HIV using a non-invasive, easy, at-home method for sample collection [52]. Similarly, the adoption
of rapid tests for malaria diagnosis resulted in safeguarding the lives of hundreds of thousands of
people, even in the most under-developed countries [57,58]. Another substantial improvement in
antibody-based rapid diagnostic methods was the incorporation of nanotechnology-principles [59].
Nanomaterials have a high surface-to-volume ratio making them suitable candidates for target-specific
attachment to the likes of antigen–antibody complexes, thereby increasing the sensitivity of tests [60,61].
The application of nano-diagnostics can hugely revolutionize the concept of accuracy and specificity in
rapid antibody detection. Over the years, global health agencies have taken an increasing interest in
infectious disease diagnosis using this robust, reproducible, and affordable means even in developing
countries [61–64].
Despite shortcomings, antibody tests have the proven advantage over NAA- or antigen-based
techniques in detecting otherwise hidden past infections within several weeks to few months. This can
be immensely crucial to gauge the true infection numbers and more realistic disease statistics as it is
difficult to diagnose all patients during their active infection phase.
4. Antibody-Based Tests for SARS and MERS: A Basis for COVID-19 Testing
Antibody-based diagnosis have historically been used in the detection of viruses, including Ebola [28],
Epstein-Barr [65], and Zika [66]. Immunoglobulin testing methods have also found applications in the
diagnosis of several coronaviruses. Earlier, coronaviruses were associated with the common cold and
other mild ailments in humans [67,68], until they took the form of aggressive outbreaks in the 21st
century viz. severe acute respiratory syndrome (SARS) [69], Middle East respiratory syndrome (MERS)
and currently COVID-19 [70] (World Health Organization, 2020). SARS-CoV and MERS-CoV, the causal
viruses for SARS and MERS, respectively, were both zoonotic in origin just like SARS-CoV-2, and they
followed similar etiologies, causing mass infections of epidemic proportions [71]. MERS, however,
followed a sporadic zoonotic spread and had restricted chains of human spread [72]. Although MERS
did not spread much beyond the Middle East and did not cause global panic, the mortality rate was
reported to be ~35% [73]. This episode following SARS, indicated the possibility of recurrence of
infectious human coronaviruses globally. In 2017, the World Health Organization (WHO) included
SARS-CoV and MERS-CoV in its Priority Pathogen list, to promote scientific investigations and develop
rapid mass diagnostic measures for similar outbreaks. Indeed, the countermeasures for SARS-CoV-2
largely utilized SARS-CoV and MERS-CoV as prototypes [74].
All infections due to coronaviruses have some similarities at the level of immunological response
(Figure 3A). During the acute phase of illness (1–7 days), detectable specific antibody responses
against coronaviral infections were rarely observed [75–77]. Marked augmentations in antibody
titers were observed after the second or third week of infection due to HCoV-229E, MERS-CoV,
and SARS-CoV infections [78–81]. In case of SARS-CoV, a very long immunological response was
observed. In symptomatic patients, there was a significant decrease in IgM antibody content after
150 days of symptoms [82–84], whereas IgG titer started to diminish after as late as 200 days.
MERS serology studies revealed a similar profile between IgM and IgG [85–87]. A steady increase
in both IgM and IgG concentration for 2–3 weeks was observed before a decline. In the case of
COVID-19, IgM expression started between 3–6 days after infection and peaked during 9–15 days of
the occurrence of symptoms [88–91]. IgG expression began after 10 days of symptoms and peaked
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between 20–30 days after the event of symptoms. IgM and IgG profiles considerably varied between
acute, severe, and critical patients (Figure 3B). However, asymptomatic patients show significant
variations in antibody profiles ranging from the lower level of expression to rapid clearance from the
blood [92]. Over the years, healthcare experts have been dependent on both binding assays (ELISA,
western blotting, immunofluorescence assay) and neutralization assays to detect the activities of
different isotypes like IgM, IgG, and IgA (Immunoglobulin A). Clinically, IgM- and IgG-based assays
are most relevant. Determining the time-window for symptom onset and detection of antibodies
against major viral disease outbreaks of this century [93], have been big steps following the successful
employment of antibody-based diagnosis. Soon after the occurrence of symptoms, both viral RNA
and proteins (antigens), especially the spike protein, are detected in the nasopharyngeal samples
(Figure 3C). Thus, NAATs and antigen tests are most effective during the first week of infection.
In contrast, they cannot give reliable results as the viral shedding and antigen generation decreases
after ten days. Although antibody production by the host’s immune system begins after a few days,
antibody detections become more dependable after 14 days since infection onset.
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Figure 3. Immunoglobulin M (IgM) and Immunoglobulin G (IgG) serology profiles of SARS, MERS,
and COVID-19, showing the time-dependent differential expression of these antibodies (A). IgM and
IgG profiles of COVID-19 cases with mild, sever and critical conditions (B). Time-dependent presence of
viral RNA/viral antigen in nasopharyngeal samples or immunoglobulins in serum of COVID-19 patients
(C). Data for plotting graphs in A for SARS serology profil [82–84], MERS serology profile [85–87],
and COVID-19 serology profile [88–91] are obtained from multiple research articles as indicated.
Figure (C) shows the general trend indicating the presence of viral RNA, antigen (in nasopharyngeal
samples) and antibodies (in blood) in a person’s body after SARS-CoV-2 infection. B is reproduced
with creative commons attribution license (CC-BY-0.4) from reference [94].
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In case of SARS-CoV, the primary antibody detection methods included ELISA,
Indirect Immunofluorescence Assay (IFA), and neutralization tests (NT) [95,96]. ELISA can detect
a blend of IgM and IgG antibodies formed within about 11 days of initial infection but involves a
long protocol. IFA consists of binding of IgM and IgG antibodies present in the patient’s serum
with specific labeled antigens or synthetic epitopes present in the test reagent. Subsequently formed
antigen–antibody complexes can be visualized and imaged under a microscope [97,98]. NT is a
quantitative test that titrates the neutralizing capability of patient sera [99], and can provide the best
correlate of immunity. However, these tests can only be performed in biosafety level 3 (BSL 3) labs
as they use viral particles. Pseudoparticle neutralization assays that use viral antigen mimicking
nanoparticles can be performed without BSL 3 facility [100]. Furthermore, immunodot that is capable
of detecting IgA, IgM, and IgG, on the same principle as western blotting using synthetic peptides and
recombinant proteins, comes at a lower cost [79,101].
ELISA and microneutralization assays using MERS virus cultured in Vero cells showed a high
degree of sensitivity and specificity [102,103] in detecting MERS virus too. On average, the antibodies
to MERS-CoV virus were detected after 10 days of the onset of the disease. Clinical observations
showed that around 42% of the results, which were tested negative for MERS-CoV by RT-PCR,
were found to be MERS-positive by immunoglobulin based PoCT such as immunofluorescence assays
and microneutralization [104]. Thus, combining antibody-based tests with NAA was a crucial step in
MERS diagnosis.
Despite the positive reports and advantages as described, no single antibody test kit could
be universally approved and commercially available for mass-testing in either of the two outbreak
episodes of SARS and MERS. This was primarily due to their inability to pass the threshold sensitivity
and specificity requirement for better positive and negative predictive values. That, in fact can serve as
a lesson, inducing wider collaborations and investments to achieve higher standards for SARS-CoV-2
antibody detection kits.
5. Development and Status of Immunoglobulin-Based Rapid Tests for COVID-19
In the wake of a global crisis in late 2019 and evolution into the COVID-19 pandemic, a pressing
need for a quick and reliable mass diagnosis method was felt by researchers, healthcare workers,
and regulatory bodies around the world [105]. Based on existing knowledge and experiences during
past viral outbreaks, the development of a scalable and rapid antibody test to be used for mass diagnosis
and surveillance seemed like a logical approach. After SARS-CoV-2 enters the human body, it migrates
to the respiratory tract, and finally infects alveolar type-II cells of lungs causing Acute Respiratory
Distress Syndrome (ARDS) [106]. The immune system produces IgM, IgG, and neutralizing antibodies,
which can block the virus from entering cells. Useful antibody tests are designed to detect the presence
of SARS-CoV-2-specific antibodies in the blood [73,107–110].
The approaches that could be used for antibody-based COVID-19 detection are broad and are
as follows:
i Binding antibody detection: these tests use specific reagents against individual isotypes such as
IgM, IgG, IgA, and are tested against purified viral proteins in BSL2 laboratories.
(a) The rapid tests or PoCTs utilize lateral flow devices for individual or combined
antibody detection.
(b) The laboratory assays are based on ELISA or chemiluminescent immunoassay (CIA).
ii Neutralizing antibody assay: these tests involve infecting and incubating cultured cells with the
virus isolated from patient samples, and then determining the functional ability of antibodies to
prevent infections in vitro.
(a) Virus neutralization tests use plaque reduction or microneutralization on clinical isolates.
(b) Pseudovirus neutralization tests, on the contrary, use recombinant pseudoviruses.
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When compared to rapid strip-based tests, the other ones are better in terms of specificity and
accuracy. Still, they are limited by the need for either BSL2 or BSL3 facilities along with specialized
tools. Lab-based tests also require trained personnel. Neutralization assays specifically are 4–5 days
long procedures.
A recent study by Chen et al. demonstrated that among antibody responses against receptor-binding
domain (RBD), spike glycoprotein type 1 (S1), ectodomain (ECD), and nucleoprotein (NP) [111]
ECD- and S1-specific IgA show neutralizing potential. This study also indicated that simultaneous
detection of NP-specific IgM and ECD-specific IgG could significantly improve the overall sensitivity.
This combined effect was more apparent in the early phase of infection (first two weeks of symptom
onset) which could be associated with development of an NP- or RBD-specific IgA immune response
in the early phase of infection and late development of IgM and IgG responses [112,113]. The binding
assays are directed towards the NP or S protein of SARS-CoV-2 virus, those epitopes being more or less
conserved (primarily the receptor-binding domain or RBD of S-protein). There still can be some degree
of cross-reactivity. Despite the fact that there can be false positives and false negatives, a rapid serology
test, as long as it has a threshold specificity (>99.5%) and sensitivity (>90%), can serve the purpose
of mass testing and surveillance according to regulatory bodies such as CDC. Many manufacturers
are currently marketing COVID-19 antibody test kits for diagnostic purposes [114]. Considering test
shortages, employers, health systems, and government bodies have been quick to buy. However, it is
to be noted that the serological tests cannot serve as an independent diagnostic tool owing to possible
false-negative results during early, yet contagious and symptomatic period, or in immuno-compromised
individuals. Furthermore, since SARS-CoV-2 was a novel virus to invade humans, there was no existing
data on the prognosis or host immunological responses to begin with. In addition to improving the
quality of rapid tests and validating their accuracy to detect the SARS-CoV-2 antibody, a thorough
understanding of the antibody dynamics was required.
As reported by Irani et al., in a correspondence to Nature Medicine, published on 16 March 2020,
the antibody-secreting cells (ASCs) registered an increase since day 7 after symptomatic presentation and
were still detectable at convalescence on day 20 [115]. Activation of CD8+ T cells and CD4+ follicular
T cells which is crucial for synergistic response to infection and inoculation by viral agents [116,117]
was also observed. In this study, the singular non-severe, symptomatic patient showed resolution of
symptoms at day 13 and was under observation till day 20. The patient’s IgM and IgG antibodies
showed a progressive increase. In a similar index case study done in Finland, immunofluorescence
assay (done on Vero E6 cells infected with SARS-CoV-2) showed the occurrence of neutralizing
antibodies, including targeted IgM and IgG after 9 days. IgG titers showed an increase from 80 to 1280
between day nine and twenty from the onset of symptoms [118].
There are several studies that validated the sensitivity and specificity of various commercially
available antibody COVID-19 tests [119]. Some of the important ones are given in Table 1. The findings
from 34 hospitalized patients presenting an acute symptomatic phase of COVID-19 suggested that
at least 32 patients showed a trend of increasing IgM and IgG up to a month after symptom onset,
with IgM reaching the average highest expression after three weeks (322.80AU/ml, ref: <10 AU/mL) [89].
IgG production started following IgM, but that continued registering a steady presence (167.16 AU/mL)
up until the last testing time point of seven weeks, while IgM expression declined after week four.
In another study, published around the same time: at 5.5 days after initial symptoms, the detection
efficiency of IgM via ELISA surpassed that of qPCR [120]. They combined the detection of IgA with
the other two IgGs and found that it followed a similar expression pattern as IgM (initial detection
~5 days). At the same time, IgG was detectable at around the usual 14 days. The dynamic range of IgM
and IgG was also quantified in serum samples of 85 confirmed (RT-PCR detectable) and 24 suspected
patients of COVID-19 at Union Hospital, Tongji Medical College of China, between 3 and 40 days after
symptom presentation [121]. These researchers employed a sandwich ELISA method with recombinant
SARS-CoV-2 nucleocapsid protein. They detected an average consistency rate of more than 85% for
IgM and IgG in both the lab-confirmed and suspected cases.
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Table 1. Various antibody-based COVID-19 tests, their features, and available validation data.
Methodology Used for
the Test Main Findings
Number of







The IgM–IgG combined assay
showed better sensitivity
than a single IgM or IgG test.
525
397 were PCR positive
and remaining 128
were negative
88.66 90.63 NA NA [114]
Chemiluminescence
assay
Showed higher efficiency for
the detection of IgM and IgG
anti-SARS CoV-2 antibodies
125
61 were PCR positive
patients and 64
were negative







IgG showed higher titre
value than that of IgM 76
43 were PCR positive
and the remaining 33 were
probable
cases
48.1 IgM 88.9 IgG 100 IgM 90.9 IgG NA NA [123]
Chemiluminescence
assay Automated CLIA analyzer 176 125 PCR confirmed cases 95–95.5 100 100 NA [124]
Chemiluminescence
assay
Positive results after two
weeks of symptom onset 34
All the subjects were PCR
confirmed
patients




observed around 20–22 days
after symptom onset






57.2 (IgM) 71.4 (IgG) NA NA NA [126]
ELISA
IgM and IgG were reliably
positive after one month of
symptom onset
24 All were PCR positivepatients 74 100 NA NA [127]
ELISA
All patients tested positive
for IgG and some patients
tested negative for IgM
60 Samples collected fromconvalescent patients
78 IgM
100 IgG NA NA NA [128]
ELISA The IgM reached 100% aboutone month of symptom onset 173
All the subjects were PCR
positive
patients
100 (>15 days) NA NA NA [112]
ELISA
IgA, IgM, and IgG were
detected from 5 days from
the onset of symptoms





NA NA NA [120]
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Table 1. Cont.
Methodology Used for
the Test Main Findings
Number






IgG and IgA ELISAs in along
with EUROLabworkstation
(Euroimmu)
39 PCR positive cases,
13 were IgG and IgA positive
and 11 IgA only positive
NA 91.9% (IgG)73.0%(IgA) NA NA [129]
IgM /IgG immunoassay The rapid test 110
30 were PCR positive
cases, 50 were persons
with respiratory
symptoms and
30 were PCR negatives
18.4 91.7 87.5 26.2 [130]
Immunochromatography
The IgM-positive rate
showed an elevation from
11.1% in early-stage to 74.2%
in late-stage disease. The
positive rate of IgG in
patients was 3.6% in
early-stage and 96.8% in
late-stage disease
105 105 patients 68.6 NA NA NA [131]
Modified cytopathogenic
assay








100 NA NA NA [132]
Immunofluorescence
assay Rapid and easy to use 59
59 suspected
patients; 24 PCR positive
cases
87.5 NA NA NA [133]
Rapid immunoassay The accuracy was 40% in thefirst week and 93.9% after 2 179
Patients included PCR
positive (n = 90)
and PCR negative
(n = 89)
85.6 91 95.1 82.7 [134]




NA NA NA [135]
Single Molecular Array




86 100 NA NA [136]
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In a letter to the editor published in Medical Virology, the authors reported that out of 60 patients,
after convalescence, 13 patients had detectable IgG and undetectable IgM. Ten patients showed a
decline in both IgM and IgG in a second test, one week after convalescence, correlative to negative
RNA tests (both times) and improvement in chest CT-scans. The results supported serodiagnosis to
be a robust indicator of the stage of COVID-19 [128]. In another cohort study, including 23 patients
(median age 62 years) with lab-confirmed COVID-19, in two Hong Kong hospitals [137], the authors
reiterated earlier reports that antibody assay can complement NAATs for diagnosis. They implemented
and advocated the use of self-collection of posterior oropharyngeal swab samples to prevent the
high exposure-risk of healthcare workers while collecting nasopharyngeal or throat swabs. The latter
methods can lodge coughing or sneezing responses by the patients. They also tested for IgM and
IgG antibodies against two different antigenic sites of the SARS-CoV-2 virus, nucleoprotein and spike
protein, with similar trends in appearance and titers. Thus, serological tests can be crucial means of
retrospective diagnosis, since microneutralization studies using recombinant spike protein, specifically,
RBD, have shown prominent results for both IgM and IgG binding and specificity [71,138–140]. Thus,
an effective antibody detection method should account for both the IgM and IgG antibodies and could
also reduce the exposure of healthcare workers by utilizing blood collection.
In a report published on 13 April 2020, M.A. Al-Muharraqi of Royal Medical Services of Bahrain
Defense Force, made an important suggestion of using serological testing as a complementary method
to repeated testing for PCR detection. He suggested that to monitor patients admitted for non-COVID
emergency surgeries, such as head and neck cancers, and to prevent postponing them. Even while
keeping in mind the various paraphernalia of antibody detection, he recommended the use of this
kind of test owing to its affordability and rapidity to monitor patients [141]. The same application can
be extended to mass containment zones such as dormitories or hospices.
A recent population screening study indicated that IgG tests targeting the S antigen (Euroimmun
and Liaison) lacked sensitivity and specificity (<95%) in clinical samples from patients exposed to
various viruses [142]. The S1 based IgA assay, in contrast, had a relatively good sensitivity [143].
When comparing the laboratory assays in patients with different severity and stages of disease (overall),
more than 14 days post-onset, the RBD based Wantai ELISA had the best overall performance.
This ELISA also showed a potential to set a threshold indicating the presence of protective
antibodies [143]. Another study indicated that Augurix IgG rapid diagnostic kit displays a relatively
high accuracy for SARS-CoV-2 IgG in high COVID-19 prevalence settings [144]. Such kits can be
suggested for mass serology testing [144,145]. Among the many currently available antibody-based
tests, the popular ones are lateral flow immunoassays (BioMedomics quick test and Surescreen rapid
test cassette), time-resolved fluorescence immunoassays (Gold site diagnostics kit), and colloidal
gold immunoassays (VivaDiag COVID-19 IgG-IgM test and Assay Genie rapid POC kit). All these
assays involve pipetting a few drops of blood from a finger prick or vein onto the immunoassay
device, followed by a couple of drops of buffer solution. The results are displayed within 10–15 min,
as depicted in Figure 4. However, some of them including BioMedomics quick test have been
temporarily withdrawn from US market due to the imposition of new policies in validation [146].
We also found a registered clinical trial protocol for VivaDiag and anticipate that further clinical
accuracy data will become available as time progresses.
J. Clin. Med. 2020, 9, 3372 13 of 26
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 13 of 26 
 
 
Figure 4. Steps in lateral flow immunoassay (LFIA)-based COVID-19 diagnosis (A). LFIA is 
performed by using the blood sample collected from the individual with suspected COVID-19 
suspected infection. Lateral flow tests involve the migration of an antigen or antigen–antibody 
complexes, through an absorbent pad which is attached at the end of the strip. A liquid sample 
containing the analyte moves through the various zones of the polymeric strip. The sample pad acts 
as sponge and once soaked it allows the fluid to pass to the second conjugate pad. The conjugate pad 
contains all the reagents required to conduct a chemical reaction between antigen and antibody. As 
the antigen passes through the pad there forms a mark. The antigen continues to pass through the 
test and control lines. After passing through these lines, the fluid enters to a porous material which 
serves as a waste container. Depending upon the patient’s condition either negative (only control 
mark developed), IgM (+) (both IgM and control marks are developed), IgG (+) (both IgG and control 
marks are developed), or both IgM and IgG (+) (all the marks are developed) results are obtained (B). 
Reproduced from reference [114] with permission from Wiley. 
6. Challenges and Pitfalls  
There are two glaring problems with the tests based on antibody detection. Firstly, almost all of 
the COVID-19 antibody-based tests that have hit the market have been reported to be of questionable 
accuracy. Most are rapid qualitative tests that can be performed in doctors’ offices, workplaces, or 
homes. Unfortunately, none of them could match the reliability of lab-based thorough antibody tests 
[147]. Some recent reports suggest that nanoparticle-based lateral immunoassays would be 
considerably more accurate [148]. Nevertheless, there needs to be further rigorous research on the 
strip-based tests for at least one or a few of them to be authorized for unrestricted universal usage. 
The second limitation of antibody testing is a lack of data on immunity. Initial studies involving small 
groups of recovered COVID-19 patients suggest that short-term immunity may occur in some 
patients. However, long-term immunity is not definitively known or understood yet. Evidence on 
related coronaviruses is scarce and sometimes conflicting. More than one study suggest that 
immunity to SARS-CoV-2 might not last very long, some of them basing this theory on evidence of 
short-lasting immunity to seasonal coronaviruses [149]. Other studies indicate that immunity to the 
original SARS-CoV lasts for at least a few years but declines in many people [150]. Recovered patients 
also show differing immune responses [92]. The reason could be due to testing limitations and lack 
of data. However, it is also possible that people with milder disease symptoms spark weaker antibody 
responses.  
Figure 4. Steps in lateral flow immunoassay (LFIA)-based COVID-19 diagnosis (A). LFIA is performed
by using the blood sample collected from the individual with suspected COVID-19 suspected infection.
Lateral flow tests involve the migration of an antigen or antigen–antibody complexes, through an
absorbent pad which is attached at the end of the strip. A liquid sample containing the analyte
moves through the various zones of the polymeric strip. The sample pad acts as sponge an once
soaked it allows the flui to pass to the second conjugate pad. The conjugate pad contains all the
reage ts required to conduct a chemical reaction between antige and antibody. As the antigen passes
through the pad there forms a m rk. Th antigen continues to pass through the test and control lines.
After passi g through these line , the fluid enters to a porous material which serves as a w ste container.
Depending upon the p tient’s condition either negative (only control mark dev loped), IgM (+) (both
IgM and control marks are developed), IgG (+) (both IgG and control marks are developed), or both
IgM and IgG (+) (all the marks are developed) resu ts are obtained (B). Re roduced from refere ce [114]
with permissi n from Wiley.
6. Challenges and Pitfalls
There are two glaring problems with the tests based on antibody detection. Firstly, almost all of
the COVID-19 antibody-based tests that have hit the market have been reported to be of questionable
accuracy. Most are rapid qualitative tests that can be performed in doctors’ offices, workplaces, or homes.
Unfortunately, none of them could match the reliability of lab-based thorough antibody tests [147].
Some recent reports suggest that nanoparticle-based lateral immunoassays would be considerably
more accurate [148]. Nevertheless, there needs to be further rigorous research on the strip-based
tests for at least one or a few of them to be authorized for unrestricted universal usage. The second
limitation of antibody testing is a lack of data on immunity. Initial studies involving small groups of
recovered COVID-19 patients suggest that short-term immunity may occur in some patients. However,
long-term immunity is not definitively known or understood yet. Evidence on related coronaviruses
is scarce and sometimes conflicting. More than one study suggest that immunity to SARS-CoV-2
might not last very long, some of them basing this theory on evidence of short-lasting immunity to
seasonal coronaviruses [149]. Other studies indicate that immunity to the original SARS-CoV lasts for
at least a few years but declines in many people [150]. Recovered patients also show differing immune
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responses [92]. The reason could be due to testing limitations and lack of data. However, it is also
possible that people with milder disease symptoms spark weaker antibody responses.
Some other factors must also be considered. A rapid serological test cannot serve as an independent
diagnostic tool owing to several reasons. Detectable amounts of antibodies appear in the patient’s
blood after a few days of the initial onset of symptoms. Although on average IgM appears in detectable
quantity after about 5 days, based on variations reported, that can be as late at 11–12 days after infection
onset [151–153]. Even in a 4–5-day window period, one can be asymptomatic but highly contagious and
can infect other people in the close surroundings. Moreover, an effective antibody detection method
should account for both the IgM and IgG antibodies, and they can vary widely between individuals.
This makes it exceedingly challenging to standardize antibody detection approaches and to use them
as a sole diagnostic tool [130,154]. A large cohort of immuno-compromised patients might give
complete false-negative results, as they would not produce antibodies like normal individuals [130].
Considering the critical question of transmissibility timeline and serologically silent cases (specifically,
in early yet active infections), rapid strip-based tests need to be used judiciously in entry/exit points
of mass transits such as airlines. In many instances, airline passengers are screened using rapid
antibody-based tests. However, there can be several COVID-19 active infections that go undetected.
That can result in contamination of the plane, and community transmissions to co-passengers.
Furthermore, antibody tests can be cross-reactive and can detect antibodies against other less severe
seasonal coronaviruses to generate false-positives [113,155,156]. To resolve such cross-reactivity issues,
it is necessary to design highly specific capture-antibodies against SARS-CoV-2 antibodies.
7. Significant Advantages and Prospects
Although the RT-PCR-based molecular test is specific and robust, it has its limitations such as
the requirement of quality patient sample viz. nasopharyngeal swab, significant quantity of viral
RNA, and chance of RNA degradation during storage and transportation. Largescale implementation
of such tests can also be restricted by need of trained professionals for sampling, lab tests, etc.
However, the most restrictive limitation could be the inability to detect past infections. In a typical
scenario, all these factors can be addressed by strictly adhering to the SOPs (Standard Operating
Procedures). Still, they generate financial and practicability issues during a pandemic. Whereas, despite
its shortcomings, moving diagnosis for COVID-19 out from laboratory infrastructure can possibly be a
breakthrough in mass testing and surveillance. Most of the investigations regarding the prognosis of
COVID-19 and its antibody dynamics tell us that the viral load detectable by RT-PCR or antigen-based
tests declines steadily after 9–10 days of initial infection [3,157,158], while IgM and IgG levels start
peaking usually after a week [93,159,160]. Thus, the sole reliance on molecular diagnostics capable of
detecting only active infections can cause serious under-detection similar to in China and the USA [161].
Antigen-tests are increasingly being considered more reliable, but they cannot possibly detect past
infections after few weeks. Rapid antibody kits are being used to perform diagnosis without sending
samples to centralized laboratories. This is helping communities without laboratory facilities identify
active and past infections [36,156,162].
Although we have had earlier episodes of viral disease outbreaks such as SARS and MERS,
none assumed pandemic proportions like the present. As COVID-19 is running rampant, researchers and
healthcare workers have faced the significant challenge of getting a handle on the correct and complete
disease statistics. A large number of cases going undetected have resulted in skewed statistics for
the total number of infections, infection mortality rates, etc. Furthermore, since this aggressive
invader resulted in many asymptomatic or pre-symptomatic patients, there is a big chance that not all
individuals can be diagnosed at the active infection stage. Hence a mass diagnostic method based
on immunoglobulins that persist in blood at least for several weeks to few months even after the
infection is resolved is a logical approach to detect the otherwise hidden cases [163]. A retrospective
diagnosis system such as antibody-based tests can undoubtedly serve the purpose of figuring
out the correct numbers while generating more information about the transmission dynamics of
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this pandemic [164]. Numerous well-designed serosurveys utilizing antibody-tests are now being
performed to this end [163–165]. These can help in developing epidemiological data and finally obtain
the much-needed complete and correct etiology and statistics of COVID-19 to help build a better
post-pandemic world [93,138]. In addition to serological tests being a practical candidate for 1st line of
diagnosis, if the instructions can be standardized for rapid kits, then combined with an extensive set of
questionnaires, these strips can be bought with prescription as a set of 3–4 tests and can be used at a
gap of 5–7 days at home.
There are several rapid antibody test devices in development that are potentially reliable as PoCT
for the diagnosis of COVID-19. Recent commercially available lateral flow test kits such as Wondfo®
SARS-CoV-2 Antibody Test (Guangzhou Wondfo Biotech Co., Ltd., Guangzhou, China), Innovita®
2019 n-CoV Ab Test Colloidal Gold (Biological Technology Co., Shanghai, China) and SGTi-flex
COVID-19 IgM/IgG (Sugentech) also showed promising results. These are gold nanoparticle-based
immuno-chromatographic test kits for qualitative determination of COVID-19’s IgM and IgG antibodies
in whole human blood, serum, or plasma. Despite their limited reliability as a diagnostic tool, antibody
testing using a relatively simple strip-based method (lateral flow chromatography) can be used to
obtain qualitative results (presence or absence of detectable quantities of IgM/IgG) in about 15 min.
However, chances of recurrent infections of COVID-19 cannot be entirely neglected. A combination
of multiple tests, including sequence comparisons of viral strains involved in multiple episodes (in
the case of recurrent infections), viral culture-based methods, and determining the innate/adaptive
immunity, could unravel the challenges in identifying these recurrences [166]. Hence, combining PCR
results with antibody detection can possibly be a reliable means of detecting recurrent infections [34].
Contextually, as one of the later developments in the COVID-19-related complications, MIS-C or
multisystem inflammatory syndrome in children needs a special mention [167–176]. On 2 May
2020, a Pediatric Intensive Care-COVID-19 international collaborative conference call was held,
where panelists recognized MIS-C as an emerging effect of COVID-19 infections in children [177].
Symptoms reported could range from two or more organ dysfunctions including cardiac, GI, renal,
neurological, respiratory disorders, conjunctivitis, systemic shock, and systemic inflammation [178].
Since June 2020, similar symptoms have been reported in adults termed MIS-A, that were usually
accompanied by respiratory failure. Notably, MIS-C or MIS-A being delayed manifestations of
SARS-CoV-2 infection, a significant percentage of these patients were observed to be PCR- and
antigen-negative, yet often antibody-positive, with varied accuracy [179,180]. These positive antibody
detections could be due to persistent multiorgan dysfunction or multisystem inflammation even after
active infection was resolved. These cases highlight the applicability of antibody-based tests to trace
past COVID-19 infections, while performing contact tracing.
Antibody testing also has a pronounced role in vaccine development. It is essential and important
to make sure that the volunteers selected for vaccine trials are free from virus-specific antibodies
in their blood to understand the formation of vaccine associated antibodies. Moreover, it is also
necessary to perform periodic testing of volunteers who have received the vaccine to understand the
effectiveness of the vaccination. Post immunization assessment of antibody levels, at least during
the trial stage, is essential to decide the time window for booster shots. Antibody-based tests would
be inevitable for assessing the efficacy of candidate vaccines by controlled human infection models
(CHIMs) too [181]. Although there are concerns regarding the possible declining antibody levels in
COVID-19 recovered patients, the concept of “immunity passports” is still an active area of discussion.
Theoretically, certification of an individual with active immunity against the virus can minimize the
burden of further testing before entering in a new geographical location where the entry is regulated.
Periodic testing of antibodies against the virus is crucial to identify the level of immunity and provide
or renew such certifications.
In addition to mass diagnosis, regulatory bodies are now employing immunoglobulin-based tests
for surveillance and control. The Centers for Disease Control and Prevention (CDC), for example,
have strategies in place to run mass antibody testing in multiple states of the USA on donated blood
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in blood banks. Simultaneously, they are planning mass antibody testing of different populations at
different time and locations [182]. Several blood banks including the American Red Cross are offering
free antibody-tests for COVID-19 to potential donors, clearly to serve the dual purpose of checking
the status of donated blood and for past infection data of the donors. Apart from diagnostic benefits,
immunoglobulin-based tests also help to identify potential donors of therapeutic plasma and provides
crucial data and knowledge for vaccine development [183].
8. Conclusions
Accurate and scalable antibody-tests for COVID-19 would increase the scope for mass surveillance
to be performed in the community. It can reduce the time to obtain an actionable result and
can have important bearings on screenings, better pandemic statistics, and epidemiological data.
Such information can help in understanding the long-term effects of infections in patients post-pandemic
and boost future pandemic preparedness. Scientists, clinicians, and public healthcare professionals
strongly believe that antibody testing using quality devices and with appropriate interpretation of the
data are of real value amidst the hyperbolic or confusing media coverage on testing. If the application
of this method is extended beyond its limited diagnostic applicability for the community testing of
COVID-19, that will undeniably have a huge impact as a surveillance tool especially for understanding
the level of immunity gained within a specific territory. Hence, in conclusion despite numerous pitfalls,
the benefits and prospects of immunoglobulin-based diagnosis and surveillance bring great value to
healthcare professionals, researchers, governments, and the public in this pandemic and post pandemic
situation, alike.
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